Three groups of biocompatible implants were created, to leverage physiological impairment caused by (i) cardiovascular, (ii) renal, and (iii) neuronal diseases. Each group of implants is subdivided into three categories according to extra functionality added plus integrated additions. The first generation contains basic functionality and the second and third generations contain extra functions. Finally, further additions can be combined and integrated. Therefore, the first group comprises of the “First Generation of Cardiovascular Implants” plus the “Second Generation of Cardiovascular Implants” plus the “Third Generation of Cardiovascular Implants” plus additional integrations named “Additions”. Equally, the second group comprises of the “First”, the “Second” and the “Third” Generation of Renal Prosthetics plus Additions. The same categorisation applies to Neural Implants, which are three generations plus additions. This can be found in the description of claims presented in the Austrian Prio (provisional patent application) number A 60273/2019, from 11 Dec. 2019.

Three groups of biocompatible implants were created, to leverage physiological impairment caused by (i) cardiovascular, (ii) renal, and (iii) neuronal diseases. Each group of implants is subdivided into three categories according to extra functionality added plus integrated additions. The first generation contains basic functionality and the second and third generations contain extra functions. Finally, further additions can be combined and integrated. Therefore, the first group comprises of the “First Generation of Cardiovascular Implants” plus the “Second Generation of Cardiovascular Implants” plus the “Third Generation of Cardiovascular Implants” plus additional integrations named “Additions”. Equally, the second group comprises of the “First”, the “Second” and the “Third” Generation of Renal Prosthetics plus Additions. The same categorisation applies to Neural Implants, which are three generations plus additions. This can be found in the description of claims presented in the Austrian Prio (provisional patent application) number A 60273/2019, from 11 Dec. 2019.

A device, a kit and a method is presented for permanently augmenting the pump function of the left heart. The mitral valve plane is assisted in a movement along the left ventricular long axis during each heart cycle. The very close relationship between the coronary sinus and the mitral valve is used by various embodiments of a medical device providing this assisted movement. By means of catheter technique an implant is inserted into the coronary sinus, the device is augmenting the up and down movement of the mitral valve and thereby increasing the left ventricular diastolic filling when moving upwards and the piston effect of the closed mitral valve when moving downwards.

An implantable medical device for transcatheter delivery, which includes an anchor unit (100) configured to be anchored at an annulus of a cardiac valve of a patient, at least one coupling unit (200) that extends along a first length radially from said anchor unit (100) towards a coaptation line of said valve and including an extension unit (400) extending along a second length. The extension unit (400) is configured to cross between the leaflets of the cardiac valve in order to fill out for an insufficient closing of the valve leaflets of said cardiac valve.

An implantable medical device for transcatheter delivery, which includes an anchor unit (100) configured to be anchored at an annulus of a cardiac valve of a patient, at least one coupling unit (200) that extends along a first length radially from said anchor unit (100) towards a coaptation line of said valve and including an extension unit (400) extending along a second length. The extension unit (400) is configured to cross between the leaflets of the cardiac valve in order to fill out for an insufficient closing of the valve leaflets of said cardiac valve.

A system or device for isolating pulmonary pressure from left atrial pressure and/or improving cardiac output. The device may be an implantable cardiac device comprising an intravascular shield. The system may comprise an intravascular shield and a trans-septal delivery sheath. The intravascular shield can be sized and configured to be positioned in a pulmonary vein or a left atrium to restrict fluid flow from the left atrium through one or more pulmonary veins to the lungs while allowing fluid flow from the lungs through the one or more pulmonary veins to the left atrium. The trans-septal delivery sheath can be configured to contain the intravascular shield in a collapsed configuration and deliver the intravascular shield to the left atrium.

An implantable medical device for transcatheter delivery, which includes an anchor unit (100) configured to be anchored at an annulus of a cardiac valve of a patient, at least one coupling unit (200) that extends along a first length radially from said anchor unit (100) towards a coaptation line of said valve and including an extension unit (400) extending along a second length. The extension unit (400) is configured to cross between the leaflets of the cardiac valve in order to fill out for an insufficient closing of the valve leaflets of said cardiac valve.

An implantable hydraulic displacement actuator comprising a biocompatible hydraulic displacement fluid for providing a force inside a human or animal body, wherein said hydraulic displacement actuator preferably is a linear hydraulic actuator for generating a cardiac movement.

The devices and method described herein allow for therapeutic damage to increase volume in these hyperdynamic hearts to allow improved physiology and ventricular filling and to reduce diastolic filling pressure by making the ventricle less stiff. For example, improving a diastolic heart function in a heart by creating at least one incision in cardiac muscle forming an interior heart wall of the interior chamber where the at least one incision extends into one or more layers of the interior heart wall without puncturing through the interior heart wall and the incision is sufficient to reduce a stiffness of the interior chamber to increase volume of the chamber and reduce diastolic filing pressure.

An implantable ventricular assist device comprises an intraventricular stent used for the creation of an artificial chamber inside the ventricle, a balloon-like structure used to drive the change of the artificial chamber between a contractile configuration and a diastolic configuration, a power system used for driving the change of the balloon-like structure between the contractile configuration and the diastolic configuration. There is also a power system and a mechanical design to operate the system working, wherein in the contractile configuration, the balloon-like structure expands and occupies the space of the artificial chamber and drives the blood inside the artificial chamber flow outside the artificial chamber, wherein in the diastolic configuration, the balloon-like structure shrinks and releases the space inside the artificial chamber, and the blood outside the artificial chamber flows back into the artificial chamber. It is easy to reach the goal of cardiac function.